Bcr-Abl

信号通路图

研究领域

抑制剂选择性比较

特异性亚型抑制剂

Abl Selective

Bcr-Abl产品

所有产品 Bcr-Abl抑制剂(24)

产品目录	产品描述	文献引用	实验数据
S1021	Dasatinib Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。	Cell, 2019, 36(2):179-193 Cancer Cell, 2019, 36(2):179-193 Nat Cell Biol, 2019, 21(6):778-790	Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.
S1026	Imatinib Mesylate (STI571) Imatinib Mesylate (STI571)是一种口服生物有效的Imatinib甲磺酸盐，是一种多靶点抑制剂，作用于v-Abl，c-Kit和PDGFR，在无细胞和细胞试验中，IC50分别为0.6 μM，0.1 μM 和0.1 μM。	Nat Cell Biol, 2019, 21(6):778-790 Mol Cell, 2019, 75(2):252-266 Autophagy, 2019, 15(12):2076-2090	THOC5 phospho-Y225 levels were assessed in the populations shown by flow cytometry following 24 h treatment with 5 μM imatinib, 150 nM dasatinib or 5 μM nilotinib. Results are displayed as mean fluorescence intensity (n= 4) ±s.e.m.
S1490	Ponatinib (AP24534) Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。	Cancer Cell, 2019, 36(2):179-193 Cell, 2019, 36(2):179-193 Cancer Cell, 2019, 36(4):431-443	RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT.
S1033	Nilotinib (AMN-107) Nilotinib (AMN-107)是一种特异性BCR-ABL抑制剂，在小鼠骨髓祖细胞中IC50低于30 nM。	Cancer Cell, 2019, 36(4):431-443 Nat Cell Biol, 2019, 21(6):778-790 J Clin Invest, 2019, 129(3):1167-1179	Effect of nilotinib on Bcr-Abl kinase activity in ABCB1- and ABCG2- overexpressing CD34⁺CD38^- cells. K562 parental cells and CD34⁺CD38^- subpopulation isolated from K562 cells were treated with nilotinib at 0.01, 0.1 and 1.0 umol/L for 12 h. Equal amount of protein was loaded for western blot analysis as described in the Experimental section. The experiments were repeated at least three times independently, and a representative experiment is shown.
S1107	Danusertib (PHA-739358) Danusertib (PHA-739358)是一种Aurora kinase抑制剂，作用于Aurora A/B/C，无细胞试验中IC50为13 nM/79 nM/61 nM，适度有效作用于Abl，TrkA，c-RET和FGFR1，对Lck，VEGFR2/3，c-Kit，CDK2等作用效果稍弱。Phase 2。	Toxicol Sci, 2019, 10.1093/toxsci/kfz123 Drug Deliv Transl Res, 2019, doi: 101007/s13346-019-00668-5 Leuk Lymphoma, 2019, 10.1080/10428194.2019.1594211	Mice bearing subcutaneous allografts of conditional patched mutant tumor cells were treated twice weekly with vehicle (saline) or 30 mg/kg PHA-739358. (B)Images of tumors. (C) Tumor weights. Each point represents a single tumor, and grey lines represent mean tumor weights, which were significantly different between vehicle and PHA-739358 treated mice (p < 0.05, based on paired two-tailed t-test).
S1134	AT9283 AT9283是一种有效的JAK2/3抑制剂，无细胞试验中IC50为1.2 nM/1.1 nM；对Aurora A/B，Abl(T315I)也有效。Phase 2。	J Clin Invest, 2018, 128(1):387-401 Nat Commun, 2018, 9(1):358 Mol Cancer Ther, 2016, 15(2):334-42	HEL cells were treated with 0.5, 1 or 5 uM of AT9283 or left untreated for 3 hrs. The expression and phosphorylation state of STAT5 (P-STAT5) and Jak2 (P-Jak2) was assessed by Western blot immunodetection.
S2243	Degrasyn (WP1130) Degrasyn (WP1130)是一种选择性deubiquitinase (DUB: USP5，UCH-L1，USP9x，USP14，和 UCH37)抑制剂，对Bcr/Abl也有抑制作用，也是一种JAK2传感器(不影响20S蛋白酶体)和转录激活剂(STAT)。	J Biol Chem, 2019, 294(12):4572-4582 Cancer Lett, 2018, 436:129-138 Cells, 2018, 10.3390/cells7080091	Protein expression by western blot analysis of cell lysates from MCF-7, TAM^R-4 and 164^R-7 cells treated for 3 days with vehicle (0.1% DMSO), 1 uM or 1.5 uM WP1130.
S1369	Bafetinib (INNO-406) Bafetinib (INNO-406)是一种有效的，选择性的，双重Bcr-Abl/Lyn双重抑制剂，无细胞试验中IC50为5.8 nM/19 nM，对T315I突变型的磷酸化没有抑制作用，对PDGFR和c-Kit的作用效果较弱。Phase 2。	J Immunol, 2016, 197(5):1587-96 Sci Rep, 2016, 10.1038/srep25694 J Med Chem, 2015,	(A) The effect of bafetinib at 3 μM on the expression levels of ABCB1 in SW620/Ad300 cells for 24, 48 and 72 h. (B) The effect of bafetinib at 3 μM on the expression level of ABCG2 in NCI-H460/MX20 cells for 24, 48 and 72 h. Equal amounts of total cell lysate were used for each sample. The effect of bafetinib at 3 μM on the subcellular localization of ABCB1 in ABCB1-overexpressing (C) SW620/Ad300 cells and (D) HEK/ABCB1 cells for 24, 48 and 72 h. The effect of bafetinib at 3 μM on the subcellular localization of ABCG2 in ABCG2-overexpressing (E) NCI-H460/MX20 cells and (F) HEK/ABCG2-R482 cells. Scale bar, 10 μm. PI (propidium Iodide, red) counterstains the nuclei.
S2158	KW-2449 KW-2449是一种多靶点抑制剂，最有效作用于Flt3，IC50为6.6 nM，作用于Flt3， Bcr-Abl和Aurora A适度有效；对PDGFRβ， IGF-1R， EGFR没有抑制效果。Phase 1。	Cell Rep, 2019, 28(9):2331-2344 Cell Chem Biol, 2018, 25(2):224-229 Mol Cancer Res, 2018, 16(10):1556-1567	Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
S2202	NVP-BHG712 NVP-BHG712是一种特异性的EphB4抑制剂，ED50为25 nM，区别于对VEGFR和EphB4的抑制，对c-Raf， c-Src和c-Abl也具有抑制活性，IC50分别为0.395 μM， 1.266 μM和1.667 μM。	J Med Chem, 2019, 10.1021/acs.jmedchem.9b00855 Cell Death Dis, 2019, 10(11):801 Photodermatol Photoimmunol Photomed, 2019, 10.1111/phpp.12520
S2622	PP121 PP121是一种作用于PDGFR， Hck， mTOR， VEGFR2， Src和Abl的多靶点抑制剂，IC50分别为2 nM， 8 nM， 10 nM， 12 nM， 14 nM和18 nM，也抑制DNA-PK，IC50为60 nM。	Biochem Biophys Res Commun, 2015, 465(1):137-44 Tumour Biol, 2014, 35(9):8659-64 Int J Clin Exp Pathol, 2013, 6(10):2082-91	PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
S2634	Rebastinib (DCC-2036) Rebastinib (DCC-2036)是一种Bcr-Abl抑制剂，作用于Abl1(WT)和Abl1(T315I)，IC50分别为0.8 nM和4 nM，也抑制SRC， LYN， FGR， HCK， KDR， FLT3，和Tie-2，对c-Kit具有低的抑制活性。Phase 1。	Nat Cell Biol, 2019, 21(2):203-213 Int J Cancer, 2018, 10.1002/ijc.31915 Int J Mass Spectrom, 2018, 10.1016/j.ijms.2017.12.002	BaF3-T674I cells were exposed to the indicated concentrations of DCC-2036, imatinib or sorafenib for 36 h, the phosphorylated PDGFRα and total PDGFRα were analyzed by immunoblotting. Imatinib was used for comparison.
S7194	GZD824 Dimesylate(HQP1351) GZD824 Dimesylate是新型口服有效的Bcr-Abl抑制剂，作用于Bcr-Abl(WT)和Bcr-Abl(T315I)，IC50分别为0.34 nM和0.68 nM。	J Leukoc Biol, 2019, 106(2):455-466 Oncotarget, 2016, 7(48):79842-79853	B. Western blot analysis of phosphorylated Akt, S6 and CrkL in T-ALL cell lines treated for 4 h with 2 μM Imatinib or Nilotinib or 0.1 μM GZD824. Twenty-five μg of protein were blotted to each lane. β-Actin documented equal lane loading. Imatinib, Nilotinib and GZD824 were abbreviated in IMA, NIL and GZD.
S2899	GNF-2 GNF-2是一种高选择性，非ATP竞争性的Bcr-Abl抑制剂，对Flt3-ITD， Tel-PDGFR， TPR-MET和Tel-JAK1转化的肿瘤细胞没有作用活性。	Cell Chem Biol, 2018, 25(2):206-214 Oncogene, 2017, 36(32):4585-4596 Oncotarget, 2017, 8(24):38717-38730	Cell viability of K562/IR cells and their parental cell lines after exposure to different concentrations of GNF-2 for 72 h.
S5254	Dasatinib hydrochloride Dasatinib hydrochloride is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.	Biomolecules, 2019, 9(11) Cancers (Basel), 2018, 10(12) Oncotarget, 2016, 7(37):59236-59244
S5205	Nilotinib hydrochloride Nilotinib hydrochloride is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.	Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.05.007 Leuk Res, 2019, 78:3-11 Blood, 2018, 131(14):1532-1544
S7782	Dasatinib Monohydrate Dasatinib Monohydrate 是一种新型有效的多靶点抑制剂，作用于靶点Abl，Src 和 c-Kit，IC50分别为 <1 nM，0.8 nM 和 79 nM。	Nanomaterials (Basel), 2019, 9(9) Blood, 2018, 131(14):1532-1544 Nat Commun, 2018, 9(1):2590	Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.
S8555	Asciminib (ABL001) Asciminib(ABL001)是一种有效的、选择性的ABL1变构抑制剂，Kd值为0.5-0.8 nM，与ABL1的十四酰口袋结合。	J Leukoc Biol, 2019, 106(2):455-466 Proc Natl Acad Sci U S A, 2018, 115(46):11766-11771 Leukemia, 2017, 31(11):2376-2387	Co-immunoprecipitation assays of UT7 BCR–ABL T315I (UT7 B/A T315I) cells with or without ponatinib (20 nm) or ABL001 (4 μm) treatment for 24 h. All protein extracts were immunoprecipitated with an anti-DNM2 antibody and immunoblotted with a pan-anti-p-Tyr antibody (4G10).
S8134	Radotinib Radotinib是一种选择性 BCR-ABL1 酪氨酸激酶抑制剂，IC50 为 34 nM，用于治疗慢性髓性白血病。
S7269	PD173955 PD173955 是一种强效的Bcr-Abl抑制剂，IC50为1-2 nM,同时也可抑制Src活性，IC50为22 nM。
S8140	GNF-7 GNF-7是一种有效的II型激酶Bcr-Abl抑制剂，对M351T，T315I，E255 V，G250E，和 c-Abl的IC50分别为 <5 nM，61 nM，122 nM，136 nM，和 133 nM。
S7526	GNF-5 GNF-5 是一种选择性的，变构的Bcr-Abl抑制剂, IC50为220 nM。	Leukemia, 2017, 31(5):1096-1107 Oncogene, 2017, 36(32):4585-4596 Oncotarget, 2017, 8(24):38717-38730	IC50 values for GNF-5-treated Ba/F3 cells expressing BCR-ABL1 or ABL1 1b mutants (a) described to confer ABL001 resistance in BCR-ABL1, (b) identified by mutagenesis screen. after 48 hours. Error bars represent SD of triplicates from three independent experiments. Significance levels in comparison with BCR-ABL1 are indicated (NS, not significant; P<0.05, P<0.01, **P<0.001, two-tailed unpaired t-test).
s9141	Berbamine Berbamine (BA), a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB.
S3609	Berbamine (dihydrochloride) Berbamine (BBM)是一种从中草药黄芦木中分离而来的双苄基异喹啉类天然产物。它是bcr/abl的新型抑制剂，具有有效的抗白血病活性，是NF-κB的抑制剂。

产品目录	产品描述	文献引用	实验数据
S1021	Dasatinib Dasatinib是一种新型有效的多靶点抑制剂，作用于Abl，Src和 c-Kit，在无细胞试验中IC50分别为 <1 nM，0.8 nM 和 79 nM。	Cell,2019, 36(2):179-193 Cancer Cell,2019, 36(2):179-193 Nat Cell Biol,2019, 21(6):778-790	Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.
S1026	Imatinib Mesylate (STI571) Imatinib Mesylate (STI571)是一种口服生物有效的Imatinib甲磺酸盐，是一种多靶点抑制剂，作用于v-Abl，c-Kit和PDGFR，在无细胞和细胞试验中，IC50分别为0.6 μM，0.1 μM 和0.1 μM。	Nat Cell Biol,2019, 21(6):778-790 Mol Cell,2019, 75(2):252-266 Autophagy,2019, 15(12):2076-2090	THOC5 phospho-Y225 levels were assessed in the populations shown by flow cytometry following 24 h treatment with 5 μM imatinib, 150 nM dasatinib or 5 μM nilotinib. Results are displayed as mean fluorescence intensity (n= 4) ±s.e.m.
S1490	Ponatinib (AP24534) Ponatinib (AP24534)是一种新型有效的多靶点抑制剂，在无细胞试验中作用于Abl，PDGFRα，VEGFR2，FGFR1和Src，IC50分别为0.37 nM，1.1 nM，1.5 nM，2.2 nM和5.4 nM。	Cancer Cell,2019, 36(2):179-193 Cell,2019, 36(2):179-193 Cancer Cell,2019, 36(4):431-443	RCH-ACV cells were treated with ponatinib(50 nM), PCI-32765(50 nM), or BMS-599626(500 nM) over a time course, and whole-cell extracts were subjected to immunoblot analysis for total or phospho-AKT.
S1033	Nilotinib (AMN-107) Nilotinib (AMN-107)是一种特异性BCR-ABL抑制剂，在小鼠骨髓祖细胞中IC50低于30 nM。	Cancer Cell,2019, 36(4):431-443 Nat Cell Biol,2019, 21(6):778-790 J Clin Invest,2019, 129(3):1167-1179	Effect of nilotinib on Bcr-Abl kinase activity in ABCB1- and ABCG2- overexpressing CD34⁺CD38^- cells. K562 parental cells and CD34⁺CD38^- subpopulation isolated from K562 cells were treated with nilotinib at 0.01, 0.1 and 1.0 umol/L for 12 h. Equal amount of protein was loaded for western blot analysis as described in the Experimental section. The experiments were repeated at least three times independently, and a representative experiment is shown.
S1107	Danusertib (PHA-739358) Danusertib (PHA-739358)是一种Aurora kinase抑制剂，作用于Aurora A/B/C，无细胞试验中IC50为13 nM/79 nM/61 nM，适度有效作用于Abl，TrkA，c-RET和FGFR1，对Lck，VEGFR2/3，c-Kit，CDK2等作用效果稍弱。Phase 2。	Toxicol Sci,2019, 10.1093/toxsci/kfz123 Drug Deliv Transl Res,2019, doi: 101007/s13346-019-00668-5 Leuk Lymphoma,2019, 10.1080/10428194.2019.1594211	Mice bearing subcutaneous allografts of conditional patched mutant tumor cells were treated twice weekly with vehicle (saline) or 30 mg/kg PHA-739358. (B)Images of tumors. (C) Tumor weights. Each point represents a single tumor, and grey lines represent mean tumor weights, which were significantly different between vehicle and PHA-739358 treated mice (p < 0.05, based on paired two-tailed t-test).
S1134	AT9283 AT9283是一种有效的JAK2/3抑制剂，无细胞试验中IC50为1.2 nM/1.1 nM；对Aurora A/B，Abl(T315I)也有效。Phase 2。	J Clin Invest,2018, 128(1):387-401 Nat Commun,2018, 9(1):358 Mol Cancer Ther,2016, 15(2):334-42	HEL cells were treated with 0.5, 1 or 5 uM of AT9283 or left untreated for 3 hrs. The expression and phosphorylation state of STAT5 (P-STAT5) and Jak2 (P-Jak2) was assessed by Western blot immunodetection.
S2243	Degrasyn (WP1130) Degrasyn (WP1130)是一种选择性deubiquitinase (DUB: USP5，UCH-L1，USP9x，USP14，和 UCH37)抑制剂，对Bcr/Abl也有抑制作用，也是一种JAK2传感器(不影响20S蛋白酶体)和转录激活剂(STAT)。	J Biol Chem,2019, 294(12):4572-4582 Cancer Lett,2018, 436:129-138 Cells,2018, 10.3390/cells7080091	Protein expression by western blot analysis of cell lysates from MCF-7, TAM^R-4 and 164^R-7 cells treated for 3 days with vehicle (0.1% DMSO), 1 uM or 1.5 uM WP1130.
S1369	Bafetinib (INNO-406) Bafetinib (INNO-406)是一种有效的，选择性的，双重Bcr-Abl/Lyn双重抑制剂，无细胞试验中IC50为5.8 nM/19 nM，对T315I突变型的磷酸化没有抑制作用，对PDGFR和c-Kit的作用效果较弱。Phase 2。	J Immunol,2016, 197(5):1587-96 Sci Rep,2016, 10.1038/srep25694 J Med Chem,2015,	(A) The effect of bafetinib at 3 μM on the expression levels of ABCB1 in SW620/Ad300 cells for 24, 48 and 72 h. (B) The effect of bafetinib at 3 μM on the expression level of ABCG2 in NCI-H460/MX20 cells for 24, 48 and 72 h. Equal amounts of total cell lysate were used for each sample. The effect of bafetinib at 3 μM on the subcellular localization of ABCB1 in ABCB1-overexpressing (C) SW620/Ad300 cells and (D) HEK/ABCB1 cells for 24, 48 and 72 h. The effect of bafetinib at 3 μM on the subcellular localization of ABCG2 in ABCG2-overexpressing (E) NCI-H460/MX20 cells and (F) HEK/ABCG2-R482 cells. Scale bar, 10 μm. PI (propidium Iodide, red) counterstains the nuclei.
S2158	KW-2449 KW-2449是一种多靶点抑制剂，最有效作用于Flt3，IC50为6.6 nM，作用于Flt3， Bcr-Abl和Aurora A适度有效；对PDGFRβ， IGF-1R， EGFR没有抑制效果。Phase 1。	Cell Rep,2019, 28(9):2331-2344 Cell Chem Biol,2018, 25(2):224-229 Mol Cancer Res,2018, 16(10):1556-1567	Western blot analysis of p-histone and histone. 0-10μM KW2449 was added.
S2202	NVP-BHG712 NVP-BHG712是一种特异性的EphB4抑制剂，ED50为25 nM，区别于对VEGFR和EphB4的抑制，对c-Raf， c-Src和c-Abl也具有抑制活性，IC50分别为0.395 μM， 1.266 μM和1.667 μM。	J Med Chem,2019, 10.1021/acs.jmedchem.9b00855 Cell Death Dis,2019, 10(11):801 Photodermatol Photoimmunol Photomed,2019, 10.1111/phpp.12520
S2622	PP121 PP121是一种作用于PDGFR， Hck， mTOR， VEGFR2， Src和Abl的多靶点抑制剂，IC50分别为2 nM， 8 nM， 10 nM， 12 nM， 14 nM和18 nM，也抑制DNA-PK，IC50为60 nM。	Biochem Biophys Res Commun,2015, 465(1):137-44 Tumour Biol,2014, 35(9):8659-64 Int J Clin Exp Pathol,2013, 6(10):2082-91	PP121 induces apoptosis in ATC cells. CAL62 cells were treated with PP121 at the indicated concentrations for 48 h, followed by PI staining. The nuclei were stained with Hoechst and analyzed using a fluorescent microscope. The representative images are shown.
S2634	Rebastinib (DCC-2036) Rebastinib (DCC-2036)是一种Bcr-Abl抑制剂，作用于Abl1(WT)和Abl1(T315I)，IC50分别为0.8 nM和4 nM，也抑制SRC， LYN， FGR， HCK， KDR， FLT3，和Tie-2，对c-Kit具有低的抑制活性。Phase 1。	Nat Cell Biol,2019, 21(2):203-213 Int J Cancer,2018, 10.1002/ijc.31915 Int J Mass Spectrom,2018, 10.1016/j.ijms.2017.12.002	BaF3-T674I cells were exposed to the indicated concentrations of DCC-2036, imatinib or sorafenib for 36 h, the phosphorylated PDGFRα and total PDGFRα were analyzed by immunoblotting. Imatinib was used for comparison.
S7194	GZD824 Dimesylate(HQP1351) GZD824 Dimesylate是新型口服有效的Bcr-Abl抑制剂，作用于Bcr-Abl(WT)和Bcr-Abl(T315I)，IC50分别为0.34 nM和0.68 nM。	J Leukoc Biol,2019, 106(2):455-466 Oncotarget,2016, 7(48):79842-79853	B. Western blot analysis of phosphorylated Akt, S6 and CrkL in T-ALL cell lines treated for 4 h with 2 μM Imatinib or Nilotinib or 0.1 μM GZD824. Twenty-five μg of protein were blotted to each lane. β-Actin documented equal lane loading. Imatinib, Nilotinib and GZD824 were abbreviated in IMA, NIL and GZD.
S2899	GNF-2 GNF-2是一种高选择性，非ATP竞争性的Bcr-Abl抑制剂，对Flt3-ITD， Tel-PDGFR， TPR-MET和Tel-JAK1转化的肿瘤细胞没有作用活性。	Cell Chem Biol,2018, 25(2):206-214 Oncogene,2017, 36(32):4585-4596 Oncotarget,2017, 8(24):38717-38730	Cell viability of K562/IR cells and their parental cell lines after exposure to different concentrations of GNF-2 for 72 h.
S5254	Dasatinib hydrochloride Dasatinib hydrochloride is the hydrochloride salt form of dasatinib, an inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.	Biomolecules,2019, 9(11) Cancers (Basel),2018, 10(12) Oncotarget,2016, 7(37):59236-59244
S5205	Nilotinib hydrochloride Nilotinib hydrochloride is the hydrochloride salt form of nilotinib, an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.	Biochem Pharmacol,2019, 10.1016/j.bcp.2019.05.007 Leuk Res,2019, 78:3-11 Blood,2018, 131(14):1532-1544
S7782	Dasatinib Monohydrate Dasatinib Monohydrate 是一种新型有效的多靶点抑制剂，作用于靶点Abl，Src 和 c-Kit，IC50分别为 <1 nM，0.8 nM 和 79 nM。	Nanomaterials (Basel),2019, 9(9) Blood,2018, 131(14):1532-1544 Nat Commun,2018, 9(1):2590	Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.
S8555	Asciminib (ABL001) Asciminib(ABL001)是一种有效的、选择性的ABL1变构抑制剂，Kd值为0.5-0.8 nM，与ABL1的十四酰口袋结合。	J Leukoc Biol,2019, 106(2):455-466 Proc Natl Acad Sci U S A,2018, 115(46):11766-11771 Leukemia,2017, 31(11):2376-2387	Co-immunoprecipitation assays of UT7 BCR–ABL T315I (UT7 B/A T315I) cells with or without ponatinib (20 nm) or ABL001 (4 μm) treatment for 24 h. All protein extracts were immunoprecipitated with an anti-DNM2 antibody and immunoblotted with a pan-anti-p-Tyr antibody (4G10).
S8134	Radotinib Radotinib是一种选择性 BCR-ABL1 酪氨酸激酶抑制剂，IC50 为 34 nM，用于治疗慢性髓性白血病。
S7269	PD173955 PD173955 是一种强效的Bcr-Abl抑制剂，IC50为1-2 nM,同时也可抑制Src活性，IC50为22 nM。
S8140	GNF-7 GNF-7是一种有效的II型激酶Bcr-Abl抑制剂，对M351T，T315I，E255 V，G250E，和 c-Abl的IC50分别为 <5 nM，61 nM，122 nM，136 nM，和 133 nM。
S7526	GNF-5 GNF-5 是一种选择性的，变构的Bcr-Abl抑制剂, IC50为220 nM。	Leukemia,2017, 31(5):1096-1107 Oncogene,2017, 36(32):4585-4596 Oncotarget,2017, 8(24):38717-38730	IC50 values for GNF-5-treated Ba/F3 cells expressing BCR-ABL1 or ABL1 1b mutants (a) described to confer ABL001 resistance in BCR-ABL1, (b) identified by mutagenesis screen. after 48 hours. Error bars represent SD of triplicates from three independent experiments. Significance levels in comparison with BCR-ABL1 are indicated (NS, not significant; P<0.05, P<0.01, **P<0.001, two-tailed unpaired t-test).
s9141	Berbamine Berbamine (BA), a traditional Chinese medicines extracted from Berberis amurensis (xiaoboan), is a novel inhibitor of bcr/abl fusion gene with potent anti-leukemia activity and also an inhibitor of NF-κB.
S3609	Berbamine (dihydrochloride) Berbamine (BBM)是一种从中草药黄芦木中分离而来的双苄基异喹啉类天然产物。它是bcr/abl的新型抑制剂，具有有效的抗白血病活性，是NF-κB的抑制剂。

研究领域

产品类型

Bcr-Abl

信号通路图

研究领域

抑制剂选择性比较

特异性亚型抑制剂

Bcr-Abl产品